Which urology hospitals and diagnostic centers in Bangladesh are best for a male patient presenting with white penile discharge and suspected infection, and what initial investigations and treatment should be done? | Rounds Which urology hospitals and diagnostic centers in Bangladesh are best for a male patient presenting with white penile discharge and suspected infection, and what initial investigations and treatment should be done? | Rounds
Loading...

Which urology hospitals and diagnostic centers in Bangladesh are best for a male patient presenting with white penile discharge and suspected infection, and what initial investigations and treatment should be done?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: July 14, 2026 · View editorial policy

Urethral discharge evaluation and empiric treatment (male)

Suspected urethral infection presenting with white penile discharge should be managed as possible sexually transmitted urethritis until proven otherwise. [1] Empiric gonorrhea and chlamydia treatment should be provided when objective evidence of urethritis is present and when follow-up or test-based treatment is not assured. [1]

Urology hospitals and diagnostic centers in Bangladesh appropriate for this presentation

  • National Institute of Kidney Disease and Urology (NIKDU), Dhaka (postgraduate institute & hospital under DGHS). [2]
  • Bangladesh Specialized Hospital (Urology department), Dhaka. [3]
  • Bangladesh Medical University (BMU) Urology department with access to BMU Super Specialized Hospital services in Dhaka. [4]

Initial investigations in suspected urethritis

  • Detailed sexual and medical history including recent sexual exposure, condom use, prior STI treatment, dysuria severity, genital ulcers, and partner STI status. [1]
  • Focused genital examination to assess for urethral discharge, meatal inflammation, genital ulcers, and concomitant scrotal pain suggestive of epididymitis/orchitis. [1]
  • NAAT testing on a urethral swab or first-catch urine for Neisseria gonorrhoeae and Chlamydia trachomatis. [1]
  • Microscopy of urethral discharge when available to support objective urethritis and guide whether empiric therapy should cover gonorrhea plus chlamydia versus chlamydia alone in low gonorrhea probability settings. [5]
  • HIV and syphilis testing should be offered as part of STI evaluation. [6]

Empiric antibiotic treatment for suspected gonorrhea and chlamydia

Empiric therapy should cover gonorrhea and chlamydia when urethritis is likely and follow-up is not reliable. [1]

  • Ceftriaxone 500 mg IM in a single dose plus doxycycline 100 mg orally twice daily for 7 days. [1]

Coverage for additional causes of non-gonococcal urethritis

Additional targeted testing and treatment for organisms beyond gonorrhea and chlamydia depend on local epidemiology and testing availability. [1]

  • Trichomonas vaginalis testing and treatment should be pursued in settings where it is prevalent or when persistent/recurrent urethritis occurs with relevant risk. [1]
  • Mycoplasma genitalium testing is recommended for persistent or recurrent NGU when available by NAAT. [1]

Partner management and counseling

  • Sex partners should be referred for evaluation and treatment when an STI is diagnosed or when presumptive treatment is provided. [1]
  • Abstinence from sex during treatment and until symptoms resolve should be advised to prevent reinfection. [1]

Treatment initiation thresholds and follow-up plan

  • **Empiric treatment is recommended when objective urethritis is present and when follow-up or test results cannot be obtained promptly. [1]
  • If symptoms persist after treatment, reassessment should include evaluation for treatment failure, reinfection, and alternative diagnoses. [1]

Common pitfalls to avoid

  • Omission of NAAT for gonorrhea and chlamydia when available, which reduces the ability to confirm diagnosis and guide resistance-aware management on recurrence. [1]
  • Delayed treatment when return follow-up is uncertain, which increases ongoing transmission risk and complicates partner management. [1]
  • Failure to test for HIV and syphilis during STI workup, despite recommendations to offer these tests. [6]

Target goals of therapy

  • Symptom resolution after treatment with appropriate empiric coverage is the primary short-term clinical goal. [1]
  • Reduction in ongoing transmission through partner treatment and behavioral counseling is a key treatment goal. [1]

Related Questions